Cargando…
“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
Autores principales: | Pantziarka, Pan, Bouche, Gauthier, André, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010551/ https://www.ncbi.nlm.nih.gov/pubmed/29962954 http://dx.doi.org/10.3389/fphar.2018.00637 |
Ejemplares similares
-
A Database of Drug Repurposing Clinical Trials in Oncology
por: Pantziarka, Pan, et al.
Publicado: (2021) -
The Repurposing Drugs in Oncology (ReDO) Project
por: Pantziarka, Pan, et al.
Publicado: (2014) -
Does the oncology community have a rejection bias when it comes to repurposed drugs?
por: Gyawali, Bishal, et al.
Publicado: (2018) -
Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014) -
Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2015)